Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), headquartered in Charlottesville, VA with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company innovating in the field of Alzheimer's disease (AD) and other neurodegenerative disorders. Acumen's core focus is on the development of novel, disease-modifying treatments by targeting toxic soluble amyloid-beta oligomers (AβOs), which are believed to be a primary underlying cause of AD. The company’s lead therapeutic candidate, sabirnetug (ACU193), is a humanized monoclonal antibody designed to selectively target these AβOs, thereby preventing synaptic dysfunction and neurodegeneration.
Acumen's scientific founders are pioneers in AβO research, contributing to decades of understanding in the field. This extensive research has culminated in the development of sabirnetug, which demonstrated positive topline results from the Phase 1 INTERCEPT-AD clinical trial. The trial showed that sabirnetug is well-tolerated, with a favorable safety profile, and demonstrated statistically significant, dose-related amyloid plaque reduction, validating its proof-of-mechanism.
Currently, Acumen is advancing sabirnetug into the Phase 2 ALTITUDE-AD trial, which aims to further evaluate its clinical efficacy and safety in early Alzheimer's disease. The company is also planning a Phase 1 study to explore a subcutaneous dosing option, enhancing patient accessibility and treatment convenience.
Acumen Pharmaceuticals remains committed to advancing its pioneering research into practical therapeutic solutions. The company's strategic partnerships, including a recent collaboration with Lonza for the manufacturing of sabirnetug, underscore its dedication to bringing effective treatments to market. With a strong financial footing, including $296.6 million in cash and marketable securities as of March 31, 2024, Acumen is well-positioned to support its clinical and operational activities into the first half of 2027.
Acumen’s mission is driven by the urgent need for safe and effective treatment options for Alzheimer's patients. Their work continues to be fueled by robust scientific insights and a commitment to improving the lives of those afflicted by AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q1 2022 financial results on May 16, 2022, at 4:30 PM ET. The company will host a conference call and a live audio webcast to discuss business performance and financial updates. Acumen is focused on developing a novel therapy for Alzheimer’s disease, specifically targeting toxic AβOs through its investigational drug, ACU193, currently in Phase I trials. Interested investors can access the live webcast via the company’s website.
Acumen Pharmaceuticals (NASDAQ: ABOS) announces publication in Frontiers in Neuroscience of preclinical evidence supporting ACU193, a monoclonal antibody targeting amyloid beta oligomers for early Alzheimer's disease treatment. The publication indicates that AβO-mediated neuronal toxicity contributes to cognitive impairments in Alzheimer's patients. Key findings include ACU193's selectivity towards AβOs without binding to plaques, suggesting a reduced risk of amyloid-related imaging abnormalities. Ongoing Phase I clinical trials aim to validate these findings and explore ACU193's therapeutic potential.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported progress on ACU193, its monoclonal antibody targeting toxic amyloid-beta oligomers, currently in Phase 1 clinical trial INTERCEPT-AD for early Alzheimer's patients. The trial has experienced slower enrollment due to COVID-19, but topline results are expected in H1 2023. Acumen ended 2021 with $225.9 million in cash, sufficient to fund operations through 2025. The company's leadership was strengthened with new appointments, including Kim Drapkin to the Board. Net losses were $100.6 million in 2021, primarily due to non-cash expenses related to fair value changes.
Acumen Pharmaceuticals (ABOS) will report its financial results for Q4 and full year 2021 on March 28, 2022, at 4:30 PM ET. The company is focused on developing targeted therapeutics for Alzheimer’s disease, particularly its investigational drug ACU193, an immunotherapy targeting toxic AβOs, currently in a Phase I clinical trial. This conference call will update stakeholders on business and financial matters, with access available via the company’s website.
Acumen Pharmaceuticals, focusing on Alzheimer’s disease therapeutics, achieved a significant milestone by enrolling the first patients in the INTERCEPT-AD Phase 1 clinical trial for its investigational drug, ACU193. This humanized monoclonal antibody selectively targets toxic amyloid-beta oligomers (AβOs). Despite delays attributed to the COVID-19 Delta variant, Acumen expects to report topline data by the end of 2022. The company reported a net loss of $92.3 million for the nine-month period ending September 30, 2021, with cash and cash equivalents totaling $135.8 million.
Acumen Pharmaceuticals, a clinical stage biopharmaceutical company focused on Alzheimer's disease, announced participation in two upcoming virtual conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 9:40 AM EST, followed by the Stifel 2021 Healthcare Conference on November 16, 2021, at 10:00 AM EST. Live webcasts will be accessible on-demand for 30 days after each event on their website. Acumen is advancing its investigational product ACU193, targeting toxic AβOs in early Alzheimer's patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced its participation in the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference, where it will present on its investigational drug ACU193. This monoclonal antibody targets toxic amyloid-beta oligomers, a key factor in Alzheimer’s disease pathology. The INTERCEPT-AD trial, currently enrolling early Alzheimer’s patients, aims to assess safety and cognitive improvements. The presentation is scheduled for November 10, 2021, and emphasizes ACU193's potential to modify disease progression with improved synaptic function.
Acumen Pharmaceuticals has initiated dosing in its Phase 1 clinical trial, INTERCEPT-AD, for ACU193, a monoclonal antibody targeting toxic amyloid-beta oligomers in early Alzheimer’s patients. This trial aims to establish safety, pharmacokinetics, and target engagement and will enroll approximately 62 participants. The CEO expressed optimism regarding ACU193's potential to meet unmet medical needs in Alzheimer’s treatment, highlighting its unique mechanism compared to other monoclonal antibodies.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 2021 financial results, highlighting substantial progress in its clinical trial for ACU193, which targets toxic amyloid-beta oligomers linked to Alzheimer’s disease. The company closed an IPO in July 2021, raising approximately $168.6 million, boosting cash reserves to over $235 million. R&D expenses rose to $2.3 million for Q2 2021, while net losses surged to $61.4 million, largely due to non-cash expenses related to warrant liabilities. The ongoing Phase 1 trial, ACU-001, is expected to yield top-line results by the end of 2022.
Acumen Pharmaceuticals (Nasdaq: ABOS) has priced its upsized initial public offering (IPO) of 9,999,999 shares at $16.00 each, raising approximately $160 million before expenses. The offering will close on July 6, 2021, with shares expected to start trading on July 1, 2021. Acumen has granted underwriters a 30-day option for an additional 1,499,999 shares. The funds will support the development of ACU193, a therapy targeting Alzheimer’s disease. The company initiated a Phase 1 clinical trial for ACU193 in Q2 2021, with results expected by the end of 2022.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
What is Acumen Pharmaceuticals’ main focus?
What is sabirnetug (ACU193)?
What were the results of the Phase 1 INTERCEPT-AD trial?
What is the Phase 2 ALTITUDE-AD trial?
What are some recent achievements of Acumen Pharmaceuticals?
What is Acumen’s financial condition?
Where is Acumen Pharmaceuticals headquartered?
What is the significance of targeting amyloid-beta oligomers (AβOs)?
What future plans does Acumen Pharmaceuticals have for sabirnetug?
How can investors get more information about Acumen Pharmaceuticals?
